5Meunier PJ, Solsman DO, Reginster JY.Strontium ranelate: dose-depentently effects in established postemenopausea vertebral osteoporosis-a 2 year randomized placebo controlled trail.J Clin Endocrinol Metab, 2002,87(4) :2063 - 2066.
6NIH Consensus Development Panel on Osteporosis Prevention, Diagnosis, and Therapy.Osteoporosis prevention, diagnosis, and therapy. JAMA, 2001, 285(3):785- 795
7Johnell O, Kanis J, Delaet C, et al. Sequential changes in quality of life after osteoporotic fractures. Osteoporos Int, 2002, 13 (Suppl11):70-76
8Albrecht WE ,Christine B ,Christoph S ,et al.Prevention of postmenopausl bone loss with long-cycle hormone replacement therapy[J]. Maturitas, 2006,53(2): 191.
9Helenius J, Kloosterboer. Tissue-selectivity: the mechanism of action of tibolone[J]. Maturitas ,2004,48(S1): S30.
10Bernard C ,Anne BL,Patrick G. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis.Effect of adding hormone replacement therapy[J]. Joint Bone Spine,2001,68:410.
8Miller BG.Osteoporosis in postmenopausal women.Therap options across a wide range of risk for fracture.Geriarics,2006,61(1):24-30.
9Osteoporosis·November 2000:Updated following publication of the up-date to the Royal College of Physieiansguideline on osteoporosis,2000.
10Cauley JA,Norton L,Lippman ME,et al.Continued breast cancerisk reduction in postmenopausal women treated with raloxifene:four-year results from the MORE trial Multiple out comes of ralox-ifene evaluation.Breast Cancer Res Treat,2001,65(2):125-127.
